STEVENSON, Md. -- (Business Wire)
The securities litigation law firm of Brower Piven, A Professional
Corporation, announces that a class action lawsuit has been commenced in
the United States District Court for the Southern District of New York
on behalf of purchasers of Prosensa Holding N.V. (“Prosensa” or the
“Company”) (NasdaqGS: RNA) common stock pursuant and/or traceable to the
Registration Statement and Prospectus (“Offering Documents”) issued in
connection with the Company’s initial public offering (“IPO”) on or
about June 28, 2013.
If you have suffered a loss from investment in Prosensa common stock in
connection with the Company’s IPO on or about June 28, 2013, and would
like to learn more about this lawsuit and your ability to participate as
a lead plaintiff, without cost or obligation to you, please visit our
website at http://www.browerpiven.com/currentsecuritiescases.html.
You may also request more information by contacting Brower Piven either
by email at hoffman@browerpiven.com
or by telephone at (410) 415-6616. No class has yet been certified in
the above action. Members of the Class will be represented by the lead
plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must
apply to be appointed lead plaintiff no later than September 16, 2014
and be selected by the Court. The lead plaintiff will direct the
litigation and participate in important decisions including whether to
accept a settlement and how much of a settlement to accept for the Class
in the action. The lead plaintiff will be selected from among applicants
claiming the largest loss from investment in Company units during the
Class Period.
The complaint accuses the defendants of violations of the Securities Act
of 1933 by virtue of the defendants’ failure to disclose that the
Offering Documents contained materially false and/or misleading
statements and/or omitted material information concerning the
development status of the drug drisapersen, the drug’s Phase II and
Phase III clinical studies, and its prospects for regulatory approval.
According to the complaint, following the Company’s September 20, 2013
announcement that the drug had not met the primary endpoint in the Phase
III study, the value of Prosensa shares declined significantly.
Attorneys at Brower Piven have extensive experience in litigating
securities and other class action cases and have been advocating for the
rights of shareholders since the 1980s. If you choose to retain counsel,
you may retain Brower Piven without financial obligation or cost to you,
or you may retain other counsel of your choice. You need take no action
at this time to be a member of the class.
Contacts:
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson,
Maryland 21153
Charles J. Piven, 410-415-6616
hoffman@browerpiven.com
Source: Brower Piven, A Professional Corporation
© 2024 Canjex Publishing Ltd. All rights reserved.